Venetoclax after idelalisib: relevant progress for CLL

Coutre et al conducted a multicenter phase 2 study on the use of venetoclax for patients with chronic lymphocytic leukemia (CLL) progressing during or after treatment with idelalisib or ibrutinib. In this issue of Blood, they report the results in 36 patients who received idelalisib as their last therapy.1 Treatment with venetoclax resulted in a high objective response rate (67%) and an estimated progression-free survival of 79% at 12 months, while reporting only moderate toxicity.